|
AU7860298A
|
|
A method of selecting pluripotent hematopoietic progenitor cells
|
|
US5683698A
|
|
Formulation for alleviating symptoms associated with arthritis
|
|
WO9616674A1
|
|
In vitro t-lymphopoiesis system
|
|
WO9613160A1
|
|
Use of urokinase-type plasminogen activators to inhibit hiv infectivity
|
|
CA2201506A1
|
|
Novel protein marker and dna encoding same
|
|
WO9606928A1
|
|
A method of selecting pluripotent hematopoietic progenitor cells
|
|
US5726153A
|
|
Synthetic peptides for arterial imaging
|
|
US5972890A
|
|
Synthetic peptides for arterial imaging
|
|
WO9522971A1
|
|
Anti-inflammatory and infection protective effects of sesamin-based lignans
|
|
US5614184A
|
|
Recombinant human erythropoietin mutants and therapeutic methods employing them
|
|
US5759542A
|
|
Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
|
|
US5397778A
|
|
Enteral formulations for treatment of inflammation and infection
|
|
US5580853A
|
|
Modified polypeptides with increased biological activity
|
|
US5413785A
|
|
Methodology employing lactobacillus GG for reduction of plasma endotoxin levels circulating in-vivo
|
|
AU6243294A
|
|
Implantable artificial organ
|
|
WO9402611A2
|
|
Recombinant human erythropoietin with altered biological activity
|
|
US5472692A
|
|
Pro-urokinase mutants
|
|
US5386832A
|
|
Liver function breath test using aromatic amino acids
|
|
AU4382593A
|
|
Extravascular system for infusion of soluble substances
|
|
AU4248193A
|
|
Quantitation of viral rna by competitive polymerase chain reaction
|
